Form 8-K Amylyx Pharmaceuticals, For: Mar 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
March 8, 2024 2:35 PM ESTGoldman Sachs analyst Corinne Jenkins downgraded Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) from Buy to Neutral with a price target of $4.00 (from $40.00).
The analyst comments "This morning, AMLX reported that the Ph3 PHOENIX trial evaluating the use of Relyvrio in patients with amyotrophic lateral sclerosis (ALS) did not meet its primary or secondary endpoints... More
